Mutant ras promotes haemopoietic cell proliferation or differentiation in a cell-specific manner

Leukemia

Volumn 10, Issue 1, 1996, Pages 83-90

  Maher, J ^a   Baker, D ^a   Dibb, N ^a   Roberts, I ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Differentiation; Haemopoiesis; Leukaemia; Ras

Indexed keywords

ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL MATURATION; CELL PROLIFERATION; GENE MUTATION; GROWTH INHIBITION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; ONCOGENE C MYC; ONCOGENE RAS; PRIORITY JOURNAL; RETROVIRUS INFECTION; SIGNAL TRANSDUCTION;

EID: 0030054152     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Barbacid M. ras genes. Ann Rev Biochem 1987; 56: 779-827.
2. Torti M et al. Erythropoietin induces p21 Ras activation and p120 GAP tyrosine phosphorylation in human erythroleukaemia cells. J Biol Chem 1992; 267: 8293-8298.
3. Satoh T, Nakafuku M, Miyajima A, Kaziro Y. Involvement of ras p21 in signal-transduction pathways from interleukin 2, interleukin 3 and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4. Proc Natl Acad Sci USA 1991; 88: 3314-3318.
4. Bortner DM, Ulivi M, Roussel MF, Ostrowski MC. The carboxy-terminal domain of the GTPase-activating protein inhibits nuclear signal transduction and morphological transformation mediated by the CSF-1 receptor Genes Dev 1991; 5: 1777-1785
5. Maher J et al. Retroviral-mediated gene transfer of a mutant H-ras gene into normal human bone marrow alters myeloid cell proliferation and differentiation. Exp Hematol 1994; 22: 8-12.
6. Andrejauskas E, Moroni C. Reversible abrogation of IL-3 dependence by an inducible H-ras oncogene. EMBO J 1989; 8: 2575-2581.
7. Baker D, Maher J, Roberts I, Dibb N. Evidence that Ras and Myc mediate the synergy between SCF or M-CSF with other growth factors. Leukemia 1994; 8: 1970-1981.
8. Litz-Jackson S, Miller AH, Burgess GS, Boswell HS. Dissociation of nuclear events on p21Ras transformation of FDC-P1 myeloid cells c-jun/AP-1 expression versus c-myc transcription. Blood 1992; 79: 2404-2414.
9. Skorski T et al. Growth factor-dependent inhibition of normal haematopoiesis by N-ras antisense oligodeoxynucleotides. J Exp Med 1992; 175: 743-750.
10. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
11. Miyauchi J et al. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood 1994; 83: 2248-2254.
12. Specchia G et al. Constitutive expression of IL-1β, M-CSF and c-fms during the myeloid blastic phase of chronic myelogenous leukaemia. Br J Haematol 1992; 80: 310-316.
13. Reilly IAG, Kozlowski R, Russell NH. Heterogeneous mechanisms of autocrine growth of AML blasts. Br J Haematol 1989; 72: 363-369.
14. Russell NH. Autocrine growth factors and leukaemic haemopoiesis. Blood Rev 1992; 6: 149-156.
15. Pietsch T. Paracrine and autocrine growth mechanisms of human stem cell factor (c-kit ligand) in myeioid leukemia. Nouv Rev Fr Hematol 1993; 35: 285-286.
16. Lowenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute myeloid leukemia. Blood 1993; 81: 281-292.
17. Prendergast AM et al. Bcr-Abl-induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb-2 adaptor protein. Cell 1993; 75: 175-185.
18. Shannon KM et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. New Engl J Med 1994; 330: 597-601.
19. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor b to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with a t(5;12) chromosomal translocation. Cell 1994; 77: 307-316.
20. ras/MAP kinase signalling pathway. Blood 1994; 83: 949-947.
21. Marshall CJ. Specificity of receptor tyrosine kinase signalling: transient versus sustained extracellular signal-related kinase activation. Cell 1995; 80: 179-185.
22. Benito M, Porras A, Nebreda AR, Santos E. Differentiation of 3T3-L1 fibroblasts to adipocytes induced by transfection of ras oncogenes. Science 1991; 253: 565-568.
23. Nakagawa T et al. Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells. Proc Natl Acad Sci USA 1987; 84: 5923-5927.
24. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976; 17: 565-577.
25. Harris P, Ralph P. Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines. J Leuk Biol 1985; 37: 407-422.
26. Bohbot A et al. U937 cell line: impact of CSFs, IL-6 and IFN-γ on the differentiation and the Leu-CAM proteins expression. Exp Hematol 1993; 21: 564-572.
27. Kitamura T et al. Establishment and characterization of a unique human cell line that proliferates dependently upon GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989; 140: 323-334.
28. Murate T, Hotta T, Yoshida S, Saito H. The close relationship between DNA replication and the selection of differentiation lineages of human erythroleukaemia cell line, K562, HEL and TF-1 cells into either erythroid or megakaryocytic lineage. Exp Hematol 1993; 21: 1084 (abstr.).
29. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-3596.
30. Karn J et al. Regulation of cell cycle duration by c-myc levels. Oncogene 1989; 4: 773-787.
31. Baker DA, Glover HR, Dibb NJ. Synergy between SCF or M-CSF with IL-3 or GM-CSF in FDC-P1 cells, a sensitive assay of transforming mutations of c-fms. Leukemia 1994; 8: 141-150.
32. Dibb NJ, Green SM, Ralph P. Expression of v-fms and c-fms in the hemopoietic cell line FDC-P1. Growth Factors 1990; 2: 301-311.
33. 2 Vitamin D3. Leukemia Res 1991; 15: 409-418.
34. Sambrook J, Frisch EF, Maniatis T. Molecular Cloning. A Laboratory Manual (2nd edn). Cold Spring Harbor Laboratory: Cold Spring Harbor NY, 1989.
35. McCoy MS, Bargmann CI, Weinberg RA. Human colon carcinoma Ki-ras2 oncogene and its corresponding proto-oncogene. Mol Cell Biol 1984; 4: 1577-1582.
36. Moscicki RA et al. Modulation of surface antigens of a human monocyte cell line, U937, during incubation with T lymphocyte-conditioned medium: detection of T4 antigen and its presence on normal blood monocytes. J Immunol 1983; 131: 743-748.
37. Larsson LG et al. Phorbol ester-induced terminal differentiation is inhibited in human U-937 monoblastic cells expressing a v-myc oncogene. Proc Natl Acad Sci USA 1988; 85: 2638-2642.
38. Liu M-y, Wu M-c. Induction of human monocyte cell line U937 differentiation and CSF-1 production by phorbol ester. Exp Hematol 1992; 20: 974-979.
39. Ziegler-Heitbrock HWL et al. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 1988; 47: 456-461.
40. Pierce JH, Aaronson SA. Myeloid cell transformation by ras-containing murine sarcoma viruses. Mol Cell Biol 1985; 5: 667-674.
41. Pharr PN, Ogawa M. Enhancement of the proliferation of murine fetal liver erythroid progenitors by infection with the Harvey sarcoma virus. Leukemia 1990; 4: 210-215.
42. Mavilio F et al. Alteration of growth and differentiation factors response by Kirsten and Harvey sarcoma viruses in the IL-3-dependent murine hematopoietic cell line 32D C13 (G). Oncogene 1989; 4: 301-308.
43. Hibi S et al. Induction of monocytic differentiation and tumorigenicity by v-Ha-ras in differentiation arrested hematopoietic cells. Blood 1993; 81: 1841-1848.
44. Katagiri K et al. Activation of Ras and formation of GAP complex during TPA-induced monocytic differentiation of HI-60 cells. Blood 1994; 84: 1780-1789.
45. Jin DI et al. Alterations in differentiation and behaviour of monocytic phagocytes in transgenic mice that express dominant suppressors of ras signalling. Mol Cell Biol 1995; 15: 693-703.
46. Bailleul B et al. Skin hyperkeratosis and papilloma formation in transgenic mice expressing a ras oncogene from a suprabasal keratin promoter. Cell 1990; 62: 697-708.
47. Padua RA et al. Ras mutations in myelodysplasia detected by amplification, oligonucleotide hybridisation and transformation. Leukemia 1988; 2: 503-510.
48. Yunis JY, Boot AJM, Mayer MG, Bos JL. Mechanisms of ras mutations in myelodysplastic syndrome. Oncogene 1989; 4: 609-614.
49. Bartram CR et al. Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci. Leukemia 1989; 3: 247-256.
50. Cogswell PC et al. Mutations of the ras proto-oncogenes in chronic myelogenous leukemia: A high frequency of ras mutations in bcr/abl rearrangement negative chronic myelogenous leukemia. Blood 1990; 74: 2629-2633.
51. Radich RP et al. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood 1990; 76: 801-807.
52. Nakagawa T et al. Case report: loss of multiple point mutations of ras genes associated with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome. Br J Haematol 1991; 77: 250-252.
53. Toksoz D, Farr CJ, Marshall CJ. ras genes and acute myeloid leukaemia. Br J Haematol 1989; 71: 1-6.
54. Neubauer A et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994; 83: 1603-1611.
55. Coghlan DW, Morley AA, Matthews JP, Bishop JF. The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia. Leukemia 1994; 8: 1682-1687.
56. Marcu KB, Bossone SA, Patel AJ. Myc function and regulation. Annu Rev Biochem 1992; 61: 809-860.
57. Sato N et al. Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common β subunit responsible for different signalling. EMBO J 1993; 12: 4181-4189.
58. Yamaguchi M, Hirayoshi K, Okuma M, Nagata K. Enhancement of differentiation induction of mouse myelomonocytic leukemia cells by extracellular ATP. J Cell Physiol 1994; 159: 441-449.